Tracking multiple markers of progress provides a more accurate and motivating picture
They also allow for consistent follow-up, accurate symptom interpretation, and reliable long-term planning
Given the markets strong demand for weight management therapies and long-term glycemic control, the agreement reflects Hanmis assessment that efpeglenatide has significant global scalability and strategic value, the company said
We promise to provide the clinical clarity you need by comparing the 15% average weight reduction of Semaglutide against the 22.5% benchmarks often seen with Tirzepatide in recent clinical trials
Additional Phase 3 trials are still underway, including TRIUMPH-2 (evaluating retatrutide in adults with obesity and type 2 diabetes) and TRIUMPH-3 (evaluating cardiovascular outcomes), with results expected later in 2026
That is the whole entry, and it is enough